1981-LB: Modeling the Impact of Semaglutide 2.4 mg in U.S. Patients with Atherosclerotic Cardiovascular Disease and BMI ≥27 kg/m2
FAURBY M, NANNA M, TOLIVER J, DOAN Q, HENRY A, SCASSELLATI SFORZOLINI T, LEVINE A, FABRICATORE A, HOUSHMAND-OEREGAARD A, MARIE NAVAR A. 1981-LB: Modeling the Impact of Semaglutide 2.4 mg in U.S. Patients with Atherosclerotic Cardiovascular Disease and BMI ≥27 kg/m2. Diabetes 2024, 73 DOI: 10.2337/db24-1981-lb.Peer-Reviewed Original ResearchNational Health and Examination SurveyAtherosclerotic cardiovascular diseaseUS adultsImpact of semaglutideMACE eventsCardiovascular diseasePotential population impactExamination SurveyPopulation impactInclusion criteriaAdverse cardiovascular eventsPotential treatment candidatesRisk reductionCensus projectionsPotential treatment effectsRisk calculatorU.S. patientsCV eventsCardiovascular eventsTrial criteriaBMIAdultsSemaglutideTherapeutic impactTreatment candidates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply